Royalty Pharma plc RPRX
Set alert
At close
Pre-market · Nov 2, 8:24 AM ET
- YTD
- +73.86%
- 1 year
- +78.96%
- Open
- 67.00
- Prev close
- 65.93
- Mkt cap
- 38.82B
- Vol
- 4.66M
- Avg vol
- 3.08M
- EPS
- 1.88
- P/E
- 35.73
- Div yield
- 1.43%
More statistics
- Low
- 66.40
- High
- 67.71
- Forward P/E
- 11.56
- Beta
- 0.41
- Short ratio
- 4.30
- Inst. own
- 88.44%
- Dividend
- 0.94
- Ex-div date
- Nov 12, 2026
- Earnings
- Nov 4, 2026
- 50-d avg
- 60.15
- 200-d avg
- 53.09
- 1y target
- 65.38
5D chart
Signals (135)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 3:40 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:15 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:00 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:50 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:30 PM | 2 days ago |
| RSI: Overbought | Oct 30, 2:00 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 1:40 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 1:30 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:55 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:50 PM | 2 days ago |
| SMA: Bearish | Oct 30, 11:45 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 11:25 AM | 2 days ago |
| MACD: Buy Signal | Oct 30, 11:10 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:40 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 10:15 AM | 2 days ago |
| SMA: Bearish | Oct 30, 10:00 AM | 2 days ago |
| RSI: Overbought | Oct 29, 3:35 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:15 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:15 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:15 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:05 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:00 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:55 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:40 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:35 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:30 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:30 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:55 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:45 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 12:45 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:35 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:15 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 12:15 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:05 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:00 PM | 3 days ago |
| SMA: Bullish | Oct 29, 11:40 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:30 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:30 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:25 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:25 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:05 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:25 AM | 3 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 4 days ago |
| SMA: Bullish | Oct 28, 3:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:30 PM | 4 days ago |
| RSI: Oversold | Oct 28, 3:10 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:45 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:25 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:10 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:10 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:05 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:00 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:55 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:45 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:25 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:20 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 12:55 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:45 PM | 4 days ago |
| SMA: Bearish | Oct 28, 11:40 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:40 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:40 AM | 4 days ago |
| SMA: Bullish | Oct 28, 11:35 AM | 4 days ago |
| SMA: Bullish | Oct 28, 11:35 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 11:35 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:30 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:30 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 11:25 AM | 4 days ago |
| SMA: Bullish | Oct 28, 11:20 AM | 4 days ago |
| SMA: Bullish | Oct 28, 11:20 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:10 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:05 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:05 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:35 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:35 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:25 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:25 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 10:20 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:10 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:05 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:00 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:55 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:55 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 5 days ago |
| MACD: Sell Signal | Oct 28, 9:30 AM | 5 days ago |
| RSI: Oversold | Oct 28, 9:30 AM | 5 days ago |
| SMA: Bearish | Oct 27, 4:00 PM | 5 days ago |
| RSI: Overbought | Oct 27, 3:35 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:20 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:20 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 3:20 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:20 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:15 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:00 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 1:55 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:50 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:15 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 1:15 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:10 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:05 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:00 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:35 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:15 PM | 5 days ago |
| SMA: Bullish | Oct 27, 11:50 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:40 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:30 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:25 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 10:50 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:40 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 10:20 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:15 AM | 5 days ago |
| RSI: Overbought | Oct 27, 9:40 AM | 5 days ago |
| SMA: Bullish | Oct 26, 3:50 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:50 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:45 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:45 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:20 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 3:20 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 2:40 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:35 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:35 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:25 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:00 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:55 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:50 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 1:50 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 1:05 PM | 6 days ago |
| SMA: Bullish | Oct 26, 11:15 AM | 6 days ago |
News
2 days ago zacks.com
Unveiling Royalty Pharma (RPRX) Q3 Outlook: Wall Street Estimates for Key Metrics
Beyond analysts' top-and-bottom-line estimates for Royalty Pharma (RPRX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the…
4 days ago fool.com
Should You Buy Royalty Pharma Stock Before Nov. 4?
Royalty Pharma shares have surged ahead of the biotech funding company's Nov. 4 quarterly earnings release. It's unclear whether the company will knock it out of the park this quarter, as was the…
2 weeks ago benzinga.com
If You Invested $1000 In Royalty Pharma Stock 15 Years Ago, You Would Have This Much Today
Royalty Pharma (NASDAQ:RPRX) has outperformed the market over the past 15 years by 6.82% on an annualized basis producing an average annual return of 19.77%. Currently, Royalty Pharma has a market…
-
3 weeks ago benzinga.com
Morgan Stanley Maintains Overweight on Royalty Pharma, Raises Price Target to $67
Morgan Stanley analyst Terence Flynn maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and raises the price target from $65 to $67.
1 month ago benzinga.com
If You Invested $100 In Royalty Pharma Stock 10 Years Ago, You Would Have This Much Today
Royalty Pharma (NASDAQ:RPRX) has outperformed the market over the past 10 years by 26.07% on an annualized basis producing an average annual return of 39.61%. Currently, Royalty Pharma has a market…
-
1 month ago benzinga.com
If You Invested $1000 In Royalty Pharma Stock 15 Years Ago, You Would Have This Much Today
Royalty Pharma (NASDAQ:RPRX) has outperformed the market over the past 15 years by 4.89% on an annualized basis producing an average annual return of 18.08%. Currently, Royalty Pharma has a market…
1 month ago benzinga.com
Why Is Eli Lilly Stock Falling Tuesday?
Eli Lilly (LLY) falls 2% amid a broader healthcare sell-off. Key support levels, technical breakdown, and market outlook analyzed.
-
1 month ago benzinga.com
TD Cowen Maintains Buy on Royalty Pharma, Raises Price Target to $68
TD Cowen analyst Michael Nedelcovych maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the price target from $65 to $68.
1 month ago benzinga.com
Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners
Novartis stock falls following Phase 3 clinical trial failures for del-desiran and pelacarsen, impacting Ionis and Royalty Pharma shares.
-
2 months ago benzinga.com
If You Invested $1000 In Royalty Pharma Stock 10 Years Ago, You Would Have This Much Today
Royalty Pharma (NASDAQ:RPRX) has outperformed the market over the past 10 years by 27.34% on an annualized basis producing an average annual return of 40.75%. Currently, Royalty Pharma has a market…
2 months ago benzinga.com
Here’s How Much You Would Have Made Owning Royalty Pharma Stock In The Last 10 Years
Royalty Pharma (NASDAQ:RPRX) has outperformed the market over the past 10 years by 26.07% on an annualized basis producing an average annual return of 39.56%. Currently, Royalty Pharma has a market…
2 months ago benzinga.com
Royalty Pharma Locks in $100M Zealand Pharma Funding Pact for Blood Disorder Drug
Royalty Pharma will pay Zealand Pharma $100 million for economic rights tied to rusfertide, with FDA action expected in Q3 of 2026.
-
2 months ago benzinga.com
JP Morgan Maintains Overweight on Royalty Pharma, Raises Price Target to $62
JP Morgan analyst Chris Schott maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and raises the price target from $58 to $62.
-
2 months ago benzinga.com
Royalty Pharma Q2 Adj. EPS $1.32 Beats $1.28 Estimate, Sales $674.000M Miss $693.190M Estimate
Royalty Pharma (NASDAQ:RPRX) reported quarterly earnings of $1.32 per share which beat the analyst consensus estimate of $1.28 by 3.13 percent. This is a 15.79 percent increase over earnings of $1.14…
3 months ago benzinga.com
AstraZeneca, GameStop, Snap And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
U.S. stock futures higher, AstraZeneca dips on merger talks, Apple down 7.4%, other stocks moving lower in pre-market trading.
-
3 months ago benzinga.com
Neurimmune Sells Portion Of Its Royalty Interest In Cliramitug To Royalty Pharma For Up To $425M, Including $125M Upfront
Neurimmune announced today that it has sold a portion of its royalty interest in cliramitug to Royalty Pharma for up to $425 million, including $125 million upfront. The transaction provides the…
-
3 months ago benzinga.com
TD Cowen Maintains Buy on Royalty Pharma, Raises Price Target to $65
TD Cowen analyst Steve Scala maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the price target from $50 to $65.
3 months ago benzinga.com
Teva Reports Early Skin Repigmentation Data, Sets Stage For Next Trial
Teva will advance TEV-'408 into a Phase 2b vitiligo study after Phase 1b data showed skin pigmentation improvements and favorable safety.
4 months ago benzinga.com
Zymeworks Targets Long-Term Cash Generation Through Theravance Acquisition
Zymeworks will acquire Theravance Biopharma for $929 million, adding YUPELRI cash flows and expanding its portfolio.
-
5 months ago benzinga.com
Citigroup Maintains Buy on Royalty Pharma, Raises Price Target to $66
Citigroup analyst Geoff Meacham maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the price target from $50 to $66.
-
5 months ago benzinga.com
JP Morgan Maintains Overweight on Royalty Pharma, Raises Price Target to $58
JP Morgan analyst Chris Schott maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and raises the price target from $50 to $58.
5 months ago benzinga.com
Royalty Pharma Reports Q1 2026 Results: Full Earnings Call Transcript
Royalty Pharma Reports Q1 2026 Results: Full Earnings Call Transcript
-
6 months ago benzinga.com
Royalty Pharma Q1 Adj. EPS $1.30 Beats $1.21 Estimate, Sales $631.000M Miss $1.235B Estimate
Royalty Pharma (NASDAQ:RPRX) reported quarterly earnings of $1.30 per share which beat the analyst consensus estimate of $1.21 by 7.44 percent. This is a 22.64 percent increase over earnings of $1.06…
-
6 months ago benzinga.com
Morgan Stanley Maintains Overweight on Royalty Pharma, Raises Price Target to $63
Morgan Stanley analyst Terence Flynn maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and raises the price target from $61 to $63.
-
7 months ago benzinga.com
Royalty Pharma Announces R&D Co-Funding Agreement With Johnson & Johnson For Total Of $500M In 2026 And 2027 To Advance Development Of JNJ-4804, Investigational Medicine For Autoimmune Diseases
Royalty Pharma plc (NASDAQ:RPRX) today announced a research and development (R&D) co-funding agreement with Johnson & Johnson for a total of $500 million in 2026 and 2027 to advance the development…
-
8 months ago benzinga.com
Zymeworks And Royalty Pharma Enter Into $250M Funding From Royalty-backed Note With Repayments Due From 30% Of Worldwide Tiered Royalties On Ziihera (Zanidatamab-hrii) Owed To Zymeworks From Jazz Pharmaceuticals And BeOne Medicines
Zymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with repayments due from 30% of worldwide tiered royalties on Ziihera until fully repaidZymeworks to retain…
-
8 months ago benzinga.com
Zymeworks Secures $250 Million From Royalty Pharma In Royalty-Backed Deal Tied To Ziihera Sales, Pledges 30% Of Future Ziihera Royalties For Repayment
Zymeworks Inc. (NASDAQ:ZYME) and Royalty Pharma plc (NASDAQ:RPRX) today announced an agreement for $250 million in funding from Royalty Pharma in the form of a non-recourse royalty-backed note with…
8 months ago benzinga.com
Royalty Pharma Q4 Earnings Report: What Investors Need to Know
Royalty Pharma Q4 Earnings Report: What Investors Need to Know
-
8 months ago benzinga.com
Royalty Pharma Q4 Adj. EPS $1.47 Beats $1.33 Estimate, Sales $622.000M Miss $795.915M Estimate
Royalty Pharma (NASDAQ:RPRX) reported quarterly earnings of $1.47 per share which beat the analyst consensus estimate of $1.33 by 10.86 percent. This is a 26.72 percent increase over earnings of…
-
8 months ago benzinga.com
Earnings Scheduled For February 11, 2026
Earnings Scheduled For February 11, 2026
-
9 months ago benzinga.com
Citigroup Maintains Buy on Royalty Pharma, Raises Price Target to $50
Citigroup analyst Geoff Meacham maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the price target from $48 to $50.
9 months ago benzinga.com
Teva Taps Royalty Pharma For $500M To Advance Skin Disease Drug
Teva and Royalty Pharma have signed a deal worth up to $500 million to advance TEV-408, a drug being tested for vitiligo and celiac disease, with new trial results expected in 2026.
-
9 months ago benzinga.com
Royalty Pharma To Reports Business Update On Jan. 13 At 44th Annual J.P. Morgan Healthcare Conference
Royalty Pharma plc (Nasdaq: RPRX) today provided an update on its business performance, including recent key accomplishments. Pablo Legorreta, Royalty Pharma's Chief Executive Officer and Chairman of…
-
9 months ago benzinga.com
Royalty Pharma Raises Quarterly Dividend From $0.22 To $0.235 Per Class A Ordinary Share
Royalty Pharma plc (NASDAQ:RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2026 of $0.235 per Class A ordinary share, reflecting a 6.8% increase in…
9 months ago benzinga.com
Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight
Pharmaceuticals giant, Merck & Co. Inc. (NYSE: MRK), is reportedly in talks to acquire cancer drug-maker Revolution Medicines Inc. (NASDAQ: RVMD) in a deal potentially valued at between $28 and $32…
10 months ago benzinga.com
What's Going On With Royalty Pharma Stock Wednesday?
Royalty Pharma has acquired PTC's remaining royalty on Roche's Evrysdi for $240 million upfront and sales-based milestones.
-
10 months ago benzinga.com
Royalty Pharma Acquires The Final Portion Of PTC Therapeutics' Remaining Royalty On Roche's Evrysdi For $240M Upfront And Up To $60M In Sales-based Milestones
Royalty Pharma plc (NASDAQ:RPRX) today announced that it has acquired the final portion of PTC Therapeutics' remaining royalty on Roche's Evrysdi for $240 million upfront and up to $60 million in…
-
10 months ago benzinga.com
Royalty Pharma Acquires Pre-Existing Royalty Interest In Nuvalent's Neladalkib And Zidesamtinib From Undisclosed Third Party For Up To $315M
Royalty Pharma plc (NASDAQ:RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent's neladalkib and zidesamtinib from an undisclosed third party for up to $315…
-
10 months ago benzinga.com
TD Cowen Maintains Buy on Royalty Pharma, Raises Price Target to $45
TD Cowen analyst Steve Scala maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the price target from $42 to $45.
11 months ago benzinga.com
Denali Flags Minimal Delay After FDA Halts Rare Disease Trial Start
FDA placed hold on Denali's drug for Pompe disease, requesting changes to protocol. No additional studies requested. Minimal delays expected.
-
11 months ago benzinga.com
Denali Therapeutics And Royalty Pharma Announce $275M Synthetic Royalty Funding Agreement Based On Future Net Sales Of Tividenofusp Alfa
Denali Therapeutics Inc. (NASDAQ:DNLI) and Royalty Pharma plc (NASDAQ:RPRX) today announced a $275 million synthetic royalty funding agreement based on future net sales of tividenofusp…
11 months ago benzinga.com
Is Royalty Pharma PLC Gaining or Losing Market Support?
Is Royalty Pharma PLC Gaining or Losing Market Support?
12 months ago benzinga.com
Stocks Rebound, Eli Lilly Jumps To 14-Month Highs: What's Moving Markets Wednesday?
Wall Street bounced back Wednesday after Tuesday's sharp selloff in AI-driven stocks, as investors bought the dip amid solid corporate earnings and growing signs that the Federal Reserve may be…
-
12 months ago benzinga.com
Royalty Pharma Q3 Adj. EPS $1.17 Beats $1.04 Estimate, Sales $609.000M Miss $739.257M Estimate
Royalty Pharma (NASDAQ:RPRX) reported quarterly earnings of $1.17 per share which beat the analyst consensus estimate of $1.04 by 12.18 percent. This is a 12.5 percent increase over earnings of $1.04…
12 months ago benzinga.com
Earnings Scheduled For November 5, 2025
Earnings Scheduled For November 5, 2025
-
12 months ago benzinga.com
Royalty Pharma Acquires Royalty Interest In Alnylam's Amvuttra From Blackstone Life Sciences For $310M
Royalty Pharma plc (NASDAQ:RPRX) today announced that it has acquired a royalty interest in Alnylam's AMVUTTRA from funds managed by Blackstone Life Sciences ("Blackstone") for $310 million. The…
-
1 year ago benzinga.com
Morgan Stanley Maintains Overweight on Royalty Pharma, Lowers Price Target to $54
Morgan Stanley analyst Terence Flynn maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and lowers the price target from $55 to $54.
-
1 year ago benzinga.com
Goldman Sachs Initiates Coverage On Royalty Pharma with Buy Rating, Announces Price Target of $42
Goldman Sachs analyst Asad Haider initiates coverage on Royalty Pharma (NASDAQ:RPRX) with a Buy rating and announces Price Target of $42.